<DOC>
	<DOCNO>NCT00100152</DOCNO>
	<brief_summary>A Notch signal pathway inhibitor study pediatric adult patient relapse ( worsen ) refractory ( respond treatment ) T-cell acute lymphoblastic leukemia/lymphoma ( T-ALL ) .</brief_summary>
	<brief_title>A Notch Signalling Pathway Inhibitor Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma ( ALL ) ( 0752-013 )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>Patients must pathologically document precursor Tcell acute lymphoblastic leukemia/lymphoma ( TALL ) , relapse refractory standard therapy , candidate standard myelosuppressive chemotherapy due age comorbid disease . Patient must performance status &lt; 2 ECOG performance status patient &gt; 16 year old ; Lansky performance level &gt; 50 patient 12 month less equal 16 year old . Patient must adequate renal liver function indicate laboratory value perform within 14 day receive first dose study drug . Patient must fully recover chemotherapy great 2 week radiotherapy , immunotherapy , systemic steroid therapy exception hydroxyurea , intrathecal therapy , immunosuppressant therapy chronic graftversushost disease prophylaxis follow allogeneic bone marrow transplant . Patient must great 2 month follow bone marrow peripheral blood stem cell transplantation immunosuppressant therapy ( exception patient take immunosuppressant therapy chronic graftversushost disease prophylaxis follow allogeneic bone marrow transplant ) . Men woman reproductive potential must use effective contraceptive method enrol study . Patient patient 's legal representative must able understand study give write informed consent . Patient treatment investigational therapy precede 30 day . Patient uncontrolled congestive heart failure , angina , myocardial infarction precede 3 month . Patient known hypersensitivity component study drug , analog , allopurinol . Patient active uncontrolled infection . Patient know psychiatric substance abuse disorder would interfere cooperation requirement trial . Patient pregnant lactating . Patient severe concurrent disease would make patient inappropriate entry study . Patient known HIV positive AIDSrelated illness . Patients `` currently active '' second malignancy , nonmelanoma skin cancer enrol . Patient isolate CNS disease .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Relapsed refractory T-cell ALL acute lymphoblastic/leukemia</keyword>
	<keyword>Relapsed/refractory T-cell acute Lymphoblastic/leukemia</keyword>
	<keyword>Acute/chronic myelogenous leukemia</keyword>
	<keyword>Poor-risk myelodysplasia</keyword>
</DOC>